Amplification of the Driving Oncogene, KRAS or BRAF , Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells-Reference-Cited by-同舟云学术

Amplification of the Driving Oncogene, KRAS or BRAF , Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells

Published:2011-03-29 Issue:166 Volume:4 Page:
ISSN:1945-0877
Container-title:Science Signaling
language:en
Short-container-title:Sci. Signal.

Author:

Little Annette S.¹,Balmanno Kathryn¹,Sale Matthew J.¹,Newman Scott²,Dry Jonathan R.³,Hampson Mark⁴,Edwards Paul A. W.²,Smith Paul D.³,Cook Simon J.¹

Affiliation:

1. Laboratory of Molecular Signalling, Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, UK.

2. Hutchison-MRC Research Centre and Department of Pathology, University of Cambridge, Hills Road, Cambridge CB2 0XZ, UK.

3. iMed Oncology, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.

4. R&D Genetics, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.

Abstract

Resistance to cancer therapeutics targeting the second kinase in a three-kinase cascade involves amplification of the upstream kinase, not the inhibited kinase.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference61 articles.

1. Targeting cancer with small molecule kinase inhibitors

2. ras oncogenes in human cancer: A review.;Bos J. L.;Cancer Res.,1989

3. Mutations of the BRAF gene in human cancer

4. Raf proteins and cancer: B-Raf is identified as a mutational target.;Mercer K. E.;Biochim. Biophys. Acta,2003

5. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition

Cited by 182 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer;Cancer Letters;2024-10

2. Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer;Frontiers in Oncology;2024-09-05

3. Unraveling the interplay between RAS/RAF/MEK/ERK signaling pathway and autophagy in cancer: From molecular mechanisms to targeted therapy;Biochemical Pharmacology;2023-11

4. Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2;International Journal of Molecular Sciences;2023-10-02

5. Stromal-derived NRG1 enables oncogenic KRAS bypass in pancreas cancer;Genes & Development;2023-09-01